Cantuzumab mertansine

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

400010-39-1

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

莫坎妥珠单抗
SB-408075
huC242-DM1

产品介绍

Cantuzumab mertansine (SB-408075; huC242-DM1) 是一种ADC，是强效美登素衍生物 (DM1; HY-19792) 和针对 CanAg 的人源化单克隆抗体 (huC242) 的免疫偶联物。Cantuzumab mertansine 对结肠癌细胞具有细胞毒性，并且对一系列 CanAg 阳性人肿瘤异种移植物具有广泛的抗肿瘤活性。

生物活性

Cantuzumab mertansine (SB-408075; huC242-DM1), anADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward coloncancercells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts^[1]^[2].

体外研究
(In Vitro)

Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 小时) 对抗原阳性 COLO 205 细胞系具有选择性细胞毒活性^[1]。

Cell Cytotoxicity Assay^[1]

Cell Line:	Antigen-positive COLO 205 cell line and the antigen-negative A-375 melanoma cell line
Concentration:	0-100 μM
Incubation Time:	24 h
Result:	Had cytotoxic activity on COLO 205 cells with an IC₅₀value of 0.032 nM (23.5 pg/ml). Had 1100-fold less cytotoxic activity for the antigen-negative A-375 cells (IC₅₀=36 nM; 26.5 ng/ml).

体内研究
(In Vivo)

Cantuzumab mertansine (SB-408075; huC242-DM1; 300 μg/kg/天; 持续 5 天) 使携带 COLO 205 结肠癌人异种移植物的小鼠完全消退和治愈^[1]。

Animal Model:	Female CB-17 SCID mice, 6-7 weeks of age bearing COLO 205 human colon tumor xenografts^[1]
Dosage:	300 μg/kg
Administration:	Daily for 5 days
Result:	Completely eliminated any measurable tumors within 2 weeks of the initiation of therapy, and all eight animals were tumor-free for 200 days (duration of the experiment).

CAS 号

400010-39-1

中文名称

莫坎妥珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.